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Abstract
Background: Cancer is one of the most difficult current health challenges, being responsible for millions of deaths
yearly. Systemic chemotherapy is the most common therapeutic approach, and the prevailing orientation calls for
the administration of the maximum tolerated dose; however, considerable limitations exist including toxicities to
healthy tissues and low achievable drug concentrations at tumor sites. Electrochemotherapy (ECT) is a tumor
treatment that combines the systemic or local delivery of anticancer drugs with the application of permeabilizing
electric pulses. In this article we evaluate the capability of ECT to allow the use of cisplatin despite its high toxicity
in a spontaneous feline model of soft tissue sarcoma.
Methods: A cohort of sixty-four cats with incompletely excised sarcomas were treated with cisplatin-based
adjuvant ECT and monitored for side effects. Their response was compared to that of fourteen cats treated with
surgery alone.
Results: The toxicities were minimal and mostly treated symptomatically. ECT resulted in increased local control
(median not reached at the time of writing) with a mean time to recurrence of 666 days versus 180 of controls.
Conclusions: We conclude that ECT is a safe and efficacious therapy for solid tumors; its use may be considered as
part of strategies for the reintroduction of drugs with a narrow therapeutic index in the clinical protocols.
Introduction
Cancer is among the major causes of death in the human
population, being responsible for millions of deaths each
year [1,2]. Systemic chemotherapy is the most commonly
used therapeutic strategy, although considerable limita-
tions exist since conventional chemotherapy often involves
pulsatile administration schedules using maximum toler-
ated doses (MTDs) of cytotoxic drugs. The long break per-
iods between therapies not only allow recovery from
various toxicities, especially myelosuppression, but also
provide an opportunity, unfortunately, for the drug-treated
tumors to recover as well [3-8]. The therapeutic index
(also known as therapeutic ratio), is a comparison of the
amount of a therapeutic agent that causes the therapeutic
effect to the amount that causes death (in animal studies)
or toxicity (in human studies). Some drugs have such a
narrow therapeutic index to be associated with significant
systemic side effects, including gastro-intestinal toxicity,
cardiac toxicity and bone marrow depletion, that could
result, among other complications, in hemorrhage and
sepsis [9-11]. Furthermore, systemic chemotherapy is
often not efficient in delivering drugs to target sites at
therapeutic concentrations, and maintaining adequate
drug levels within tumors is a challenge [2-14]. Che-
motherapeutic delivery to solid tumors systemically
involves several limiting factors, including the role of the i)
drug transport along the blood circulatory system to tis-
sues (including also the issue of plasma binding proteins),
ii) interstitial space, iii) drug removal by capillaries and,
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respect to the drug distribution [1,12-14]. As a result, only
a fraction of the administered dose reaches tumor cells,
which dramatically hinders tumor targeting, prevents
effective therapy and increases toxicity to healthy tissue
[1,12-14]. Considering that more than 85% of human can-
cers are solid tumors [8], several strategies have been
adopted to overcome these problems, including intra-
arterial chemotherapy [15], chemotherapy impregnated
implants [16-18] and polymeric drug delivery systems [8].
Despite the continuous investigation of alternate routes
for improved systemic chemotherapeutic delivery there
has been minimum therapeutic gain [8,15-18], therefore
localized delivery has gained increased attention in cancer
therapy. This strategy aims at maintaining low systemic
drug levels while ensuring therapeutic levels at target sites,
thus aiming to deliver a much more efficient drug therapy
[8,14]. Selective drug retention at target sites, with conse-
quent decreased systemic drug exposure, is an important
issue, since two therapeutic goals are minimizing toxicity
and maximizing efficacy [19]. This selectiveness can be
accomplished through electrochemotherapy (ECT) a can-
cer treatment that involves the application of permeabilizig
electric pulses having appropriate waveforms coupled with
the local or systemic administration of chemotherapy
agents [20,21]. Over the past years, several ECT studies
have been conducted on companion animals affected by
advanced spontaneous tumors, obtaining high response
rates, while surgery alone, especially for rapidly growing
tumors such as feline sarcomas results in control times
ranging from 60 to 270 days [22-25]. Cisplatin is a che-
motherapy agent widely adopted in veterinary oncology
that cannot be administered systemically to cats since it
induces severe pulmonary toxicoses including dyspnea,
hydrothorax, pulmonary edema, mediastinal edema and
death [26,27]. Aim of this investigation is the evaluation of
toxicoses and efficacy of local cisplatin as agent for adju-
vant ECT in a spontaneous feline sarcoma model.
Methods
T h eR e g i n aE l e n aC a n c e rI n s t itute Ethical Committee
approved this study that was performed according to
the Italian Law (116/92). Seventy-eight privately owned
cats with histopathologically confirmed incompletely
excised or recurring soft tissue sarcoma (STS) were
entered in the modified phase II study. Evidence of
recurrence was demonstrated upon the diagnostic histo-
pathology analysis of bioptic specimens excised by the
referring veterinarians. Previous informed consent was
obtained from the owners. In order to be enrolled in the
study, patients had to fulfill the following criteria:
1. Accessibility of the neoplasm location.
2. Absence of distant metastases.
3. Compliance of the owner for follow-up rechecks.
4. Absence of other life-threatening diseases.
5. Overall performance status, assessed according to
the modified Karnowsky system, had to be less than 3
[19,23].
Staging process included a thorough anamnesis, histo-
pathologic assessment of surgical margins, physical exami-
nation, complete blood cell count (CBC), serum
biochemistry profile, urinalysis thoracic radiographs (three
projections), and abdominal ultrasonography. In order to
confirm the diagnoses, histological examination of the
biopsies was performed following standard protocols, using
Hematoxylin/Eosin and Hematoxylin/Van Gieson stain-
ings. Patients receiving adjuvant ECT were matched with a
cohort of cats treated with surgery alone, having the own-
ers declined to pursue other treatments than surgery.
Treatment
Patients received two rounds of ECT 1 week apart at a vol-
tage of 1,300 V/cm delivered through caliper electrodes,
beginning 1 week after tumor excision. The surgical suture
and 3 cm of apparently normal tissue (up to 1.5 cm depth)
were locally injected with cisplatin at a concentration of
0.5 mg/ml. All the ECTs were given after sedation with
medetodimine and ketamine following the manufacturers’
instruction followed by administration of propofol. Five
minutes after the infiltration of the anticancer agent, trains
of eight biphasic electric pulses lasting 50 + 50 ms each,
with a frequency of 1 Hz, and with 1-ms interpulse inter-
vals (total treatment time: 7.1 ms/cm
2 of treated area),
were generated by a Chemipulse III portable electropora-
tor (EU patent application number 2221086) and delivered
by means of modified caliper electrodes with 1 cm dis-
tance between the plates.
Follow-up evaluations
A CBC, serum biochemistry profile and urinalysis were
performed prior and 1 week after each dose of cisplatin. A
monthly recheck was scheduled after the completion of
the treatment. Thoracic radiographs were taken on a 3
months base until a 1 year follow-up was reached. Recur-
rence was proved by cytopathology or histopathology.
Endpoints
During the ECT sessions the patients were checked using
cardiac monitor and pulse oxymeter. The primary end-
point was the evaluation of cisplatin-related toxicoses
(cutaneous, respiratory, gastrointestinal, hematological or
renal); the secondary endpoint was the time of tumor
recurrence. However, at the time of tumor recurrence, a
second course of surgery and ECT was offered to the
owner considering its high success rate in selected patients
[23,25].
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A univariate survival analysis for each prognostic vari-
able on overall survival was estimated according to the
Kaplan-Meier method [28]. The terminal event was
tumor recurrence. The mean time to recurrence is
described as the median time and the mean time (add-
ing in the last case the range). The statistical signifi-
cance of the differences in control time among the
prognostic groups was evaluated by the log-rank test
[29]. P values < 0.05 was regarded as statistical signifi-
cant in two-tailed tests. SPSS software (version 11.5,
SPSS, Chicago) was used for the statistical analysis.
Results
Sixty-four cats entered the electrochemotherapy study
over a 5 years period and their response has been
matched with that of 14 cats treated with surgery alone.
Hematological, gastrointestinal and renal toxicity
Hematological toxicity was not evidenced among the 64
patients of the ECT study. Three patients (4.5%) devel-
oped gastrointestinal symptoms, mostly consisting of
anorexia lasting 3-5 days, responsive to anti-emetic ther-
apy with metoclopramide. One patient, a seven-year-old
cat, died of renal failure, probably unrelated to the treat-
ment as suggested by the current literature [23].
Muscular side effects All the patients experienced tran-
sient muscular contractions at the time of the treatment,
which were more pronounced in those cats whose tumor
was located nearby nerve roots. These contractions did
n o tr e s u l ti np a i no rd i s c o m f o r tf o rt h ep a t i e n t sw h e n
t h e yr e c o v e r e df r o mt h es e d a t i o na n dd i dn o tr e q u i r e
symptomatic therapy.
Cardiorespiratory side effects Neither cardiac distur-
bances related to the electrical stimulation nor pulmon-
ary distresses related to the administration of cisplatin
were evidenced during the study.
Cutaneous side effects D e s p i t et h eu s eo fe l e c t r o c o n -
ductive gel, seven patients had small electrode-induced
burns which exited in 1 cm long, 1 mm wide discolored
scars. These scars tended to disappear within 2-3 weeks
as previously reported [23,25].
Soft tissue side effects Three cats had a local inflamma-
tion involving the deep subcutaneous connective tissues,
which led to compulsive scratching. This phenomenon,
in one patient, led to wound dehiscence that needed re-
suturing. In the other two cats the inflammation was suc-
cessfully managed through the administration of the non
steroidal anti-inflammatory drug meloxicam for a period
of one week.
Treatment efficacy
Out of the 14 cats that underwent surgery only, one
patient is still in remission (in excess of one year) at the
time of writing, while the remaining 13 cats had recur-
rence of the tumor at different times. Median time to
recurrence was 180 days (Figure 1); mean time to recur-
rence was 213 days (range 131-294 days). Due to the
aggressive nature of the tumors, the owners of these
cats declined further treatments at the time of local
recurrence.
Out of the 64 cats enrolled in the ECT study, eight died
of the following unrelated pathologies: four died of
causes related to advanced age, one died of renal failure,
one died of FeLV infection, one died of metastatic carci-
noma and one died of metastatic fibrosarcoma, and
therefore were censored in the statistical analysis. Finally,
19 (29.7%) cats had tumor recurrence at different times.
Four of the recurring tumors were amenable to another
course of surgery and adjuvant ECT experiencing control
times that were of 300 days for one patient (at that time
the tumor recurred and the owner declined further thera-
pies), and in excess of 120, 300 and 565 for the remaining
three. Median time to recurrence for the ECT cohort was
not reached at the time of article writing, while mean
time to recurrence was 666 days (range 535-797 days).
Figure 1 shows the Kaplan-Meier curve for both cohorts
participating the study. The only statistical significant
parameter was the ECT treatment (P = 0.0002), on the
contrary the following statistical factors failed to reach
the statistical significance: gender, age, site of primary
tumor and dimension (measures as three-dimensional
volume).
Discussion
Cancer is one of the most difficult health challenges of our
time. In addition to the currently available conventional
Figure 1 Treatment outcome: Kaplan-Meier time to recurrence
curve for cats treated with surgery (blue line) and cats treated
with the combination of surgery and ECT (green line).
Spugnini et al. Journal of Translational Medicine 2011, 9:152
http://www.translational-medicine.com/content/9/1/152
Page 3 of 5therapeutic modalities such as chemotherapy, radiotherapy
and surgery, there is an urgent need for more effective and
less toxic therapies for solid malignancies. Chemotherapy
alone shows high toxicity and a low survival rate [6,7]. In
some cases, malignant cells develop resistance to a parti-
cular drug and to combat this, a variety of approaches like
intra-arterial therapy, induction chemotherapy, immu-
notherapy, and photodynamic therapy have been
employed [8]. Techniques like intra-arterial and induction
chemotherapy have showed some improvement in survival
rate. Immununotherapy is in the experimental stages,
while photodynamic therapy is being clinically applied, but
side effects prevented its diffusion. Various treatment stra-
tegies have been explored to improve upon current sys-
temic chemotherapy methods. Localized pulse mediated
delivery of chemotherapeutics for solid tumors is one
approach that has been explored in recent years due to the
customizability of the therapy [20,24]. However, some
concerns still need to be addressed. One challenge of loca-
lized electrochemotherapy is the lack of control in drug
distribution when treating solid tumors. Intravenously
delivered chemotherapeutics must overcome barriers
including the vasculature wall. Moreover, hypoxic tumor
regions distant from vasculature may not be exposed to
adequate amounts of drug, thus developing multi-drug
resistance. On the other hand, drug penetration following
intralesional administration is hindered by the extravascu-
lar compartment of tumor tissue, which limits drug diffu-
sion [19,30]. In this study, to overcome the above
limitations, ECT has been used in an adjuvant fashion,
after tumor resection, thus limiting its purpose to the era-
dication of the surviving clonogenic cells and the preven-
tion of tumor recurrence. More importantly, the rapid
shifting of cisplatin from the interstitial space to within
the tissue, prevented potentially fatal toxicities in this
feline model of solid tumor. Furthermore, the increased
susceptibility of tumor cells to the permeabilizing pulses,
compared to that of normal tissues, allows a semi-selective
drug delivery [19-25], therefore supporting tumor control
while side effects are minimized. The results in terms of
local control suggest a therapeutic gain when ECT is
added to the surgical protocol and compare favorably with
the results obtained by our group in a previous study of
ECT in cats with soft tissue sarcomas [23]. In that investi-
gation bleomycin has been used since it is the first choice
drug for ECT. Cisplatin is a second choice drug for ECT
and its systemic administration in cats is not possible due
to fatal pulmonary edema [26,27]. Indeed one of the aims
of our study was to evaluate the reintroduction of highly
toxic compounds through electroporation in the antican-
cer protocols. The simple strategy of using electroporation
allowed us to greatly increase the therapeutic index of cis-
platin in cats, which are very susceptible to this drug. It is
conceivable that the increased adoption of this strategy by
other investigators will result in the “rescue” of other
drugs that otherwise would not be clinically usable, due to
excessive systemic toxicity. Also, it is noticeable that only
one ECT patient experienced metastatic spread of the pri-
mary tumor. The low frequency of this event (1/64, i.e.,
~1.6%) compares favorably with what observed in our pre-
vious investigation of cats with sarcomas, and more
importantly, with the much higher metastatic incidence
reported in the literature (depending on the studies it
ranges from 10% to 25%) [23].
Conclusion
ECT is an effective strategy to improve the chemother-
apy efficacy and the therapeutic index of chemotherapy
drugs in the treatment of solid neoplasms. Further stu-
dies with a greater number of patients and, possibly,
involving multiple institutions should be performed in
order to better elucidate the real clinical impact of ECT
on STS treatment in feline patients, also in view of a
possible translation to humans [24].
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